Medarex and MedImmune Collaborate to Develop Human Antibodies

Strategic Insights -

Medarex and MedImmune announced a partnership to develop fully human antibodies using Medarex's HuMAb-Mouse technology. Under the agreement, MedImmune gains exclusive rights to the technology for the development of antibodies against respiratory syncytial virus (RSV) and an option to further license the technology for additional antigens. Medarex will receive technology access fees, potential license and milestone payments, and royalties on product sales.

Key Takeaways:

  • Medarex and MedImmune signed an agreement to develop fully human antibodies using Medarex's HuMAb-Mouse technology.
  • MedImmune receives exclusive, worldwide license for the use of HuMAb-Mouse technology for RSV antibodies and an option to further license for additional antigens.
  • Medarex will receive technology access fees, potential license and milestone payments, and royalties on product sales.
  • MedImmune has manufacturing facilities in Frederick, Maryland, and Nijmegen, the Netherlands, and an oncology subsidiary in West Conshohocken, Pennsylvania.
  • Medarex has a broad platform of patented technologies for antibody discovery and development, including HuMAb-Mouse, TC Mouse, and Trans-Phage Technology.
  • The partnership aims to develop monoclonal antibody-based therapeutics for cancer and other life-threatening diseases.

Statistics:

  • Medarex and MedImmune have a partnered to develop antibodies against respiratory syncytial virus (RSV).
  • Medarex's HuMAb-Mouse technology will be used exclusively by MedImmune for RSV antibody development.
  • Medarex will receive royalties on product sales from the partnership.
  • Medarex has a range of patented technologies for antibody discovery and development.
  • Medarex's Trans-Phage Technology combines high-throughput screening with fully human antibody development.

Sources:

  • Medarex, Inc., Press Release, 1999
  • MedImmune, Inc., Annual Report on Form 10-K for the fiscal year ended December 31, 1999
  • U.S. Securities and Exchange Commission (SEC), public disclosure filings, 1999